Objetivo
Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012. The frequency of complications after surgery is relatively high, but rapid and safe monitoring methods are missing.
MD Biomedical AB has addressed this need and developed a radically new and innovative piece of medical equipment that is gently attached on the surface of the bowel for sampling of biomakers. This makes it possible to detect complications within minutes, at an early stage of illness, and long before patient systemic indications.
The possibility of rapid counteractions improves the treatment of the patient and save health care costs.
The feasibility study comprises one work package divided in 6 tasks and shall in measurable terms assess the functional, medical, economic, and environmental effects and the deliverable is a feasibility report including a business plan.
Ámbito científico
Programa(s)
Tema(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-1-2014
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
90719 UMEA
Suecia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.